Page last updated: 2024-11-13
mitorubrin
Description
mitorubrin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
mitorubrin : An azaphilone that is 7,8-dihydro-6H-2-benzopyran substituted by a methyl group at position 7, oxo groups at positions 6 and 8, a propenyl group at position 3 and a (2,4-dihydroxy-6-methylbenzoyl)oxy group at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (7)
Synonym |
7-methyl-6,8-dioxo-3-[(1e)-prop-1-en-1-yl]-7,8-dihydro-6h-isochromen-7-yl 2,4-dihydroxy-6-methylbenzoate |
CHEBI:50943 , |
mitorubrin |
NCGC00160986-01 |
CHEMBL1411846 |
Q27122254 |
[7-methyl-6,8-dioxo-3-[(e)-prop-1-enyl]isochromen-7-yl] 2,4-dihydroxy-6-methylbenzoate |
Drug Classes (2)
Class | Description |
azaphilone | Any member of a family of natural products which contains a 6H-isochromene-6,8(7H)-dione or an isoquinoline-6,8(2H,7H)-dione skeleton and its substituted derivatives thereof. |
beta-diketone | A diketone in which the two keto groups are separated by a single carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (3)
Potency Measurements
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.22 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.42 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |